A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis
Open Access
- 31 March 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (3) , 472-478
- https://doi.org/10.1016/j.jaad.2005.10.061
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- PsoriasisThe Lancet, 2003
- Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyJournal of the American Academy of Dermatology, 2002
- Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort studyJournal of the American Academy of Dermatology, 2001
- Two considerations for patients with psoriasis and their clinicians:: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?Journal of the American Academy of Dermatology, 2000
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized studyBritish Journal of Dermatology, 1999
- Cyclosporine consensus conference: With emphasis on the treatment of psoriasisJournal of the American Academy of Dermatology, 1998
- The economic impact of psoriasis increases with psoriasis severityJournal of the American Academy of Dermatology, 1997
- Cyclosporine as maintenance therapy in patients with severe psoriasisJournal of the American Academy of Dermatology, 1997
- Cyclosporine for Plaque-Type PsoriasisNew England Journal of Medicine, 1991